17:52 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
00:03 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Allergan's modified abicipar pegol decreases intraocular inflammation

Ahead of a BLA submission to FDA this half for AMD therapy abicipar pegol, Allergan and Molecular Partners reported top-line safety data from the Phase II MAPLE trial showing that an optimized formulation of the...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
16:02 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week...
20:48 , Jul 19, 2018 |  BC Extra  |  Clinical News

Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
20:36 , May 12, 2017 |  BC Week In Review  |  Clinical News

Allergan completes enrollment in Phase III trials for AMD

Allergan plc (NYSE:AGN) completed enrollment of 1,800 total patients with wet age-related macular degeneration (AMD) in the Phase III CEDAR and SEQUOIA trials comparing abicipar pegol (AGN-150998, MP0112) vs. Lucentis ranibizumab. The double-blind, sham-controlled, international...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Abicipar pegol: Phase II data

The double-blind, sham-controlled, U.S. Phase II PALM trial in 151 DME patients showed that 1 mg intravitreal abicipar pegol every 8 weeks, 2 mg abicipar pegol every 8 weeks and 2 mg abicipar pegol every...